Clinical Trials · NCT01624259
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 599
- Start date
- Jun 2012
- Locations
- 57 sites, 10 countries
- Primary endpoint
- Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)